• Home
  • About
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Investors/Media
  • Contact
Contact Icon Contact Icon Contact Icon
  • Home
  • About
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Investors/Media
  • Contact
  • Home
  • About
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Investors/Media
  • Contact
Single Image

Robyn Hunter

Robyn Hunter joined our Board in 2022.  She has served as the Chief Financial Officer of SOTIO Biotech since August 2022. Previously, she worked as CFO for Fortress Biotech, Inc. since June 2017 and from August 2011 to June 2017, she served as the Vice President and Corporate Controller.  Ms. Hunter served as Senior Vice President and Chief Financial Officer of Schochet Associates, Inc. from January 2006 to May 2011.  She served as the Corporate Controller for Indevus Pharmaceuticals, Inc. from August 2004 to January 2006.  Ms. Hunter held several positions from Accounting Manager to Vice President and Treasurer of The Stackpole Corporation from 1990 to 2004.  She holds a B.A. in Economics from Union College in Schenectady, New York.

  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Contact
    • Email

Tenax Therapeutics

Specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension.

Contact Icon Contact Icon Contact Icon

© Copyright 2023 Tenax Therapeutics. All Rights Reserved.
Site created by Top Shelf Design

  • Privacy Policy
  • Terms of Service